Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116261966 | 11626196 | 6 | F | 20150825 | 20160725 | 20151013 | 20160802 | EXP | GB-BAUSCH-BL-2015-022639 | BAUSCH AND LOMB | 77.00 | YR | M | Y | 172.00000 | KG | 20160802 | OT | GB | GB |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
116261966 | 11626196 | 1 | PS | PREDNISOLONE. | PREDNISOLONE | 1 | Oral | U | 40070 | 100 | MG | QD | |||||||
116261966 | 11626196 | 2 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | U | 40070 | |||||||||||
116261966 | 11626196 | 3 | SS | OMEPRAZOLE. | OMEPRAZOLE | 1 | Oral | U | 0 | 40 | MG | QD | |||||||
116261966 | 11626196 | 4 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | U | 0 | 1400 | MG | QD | |||||||
116261966 | 11626196 | 5 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | U | 0 | |||||||||||
116261966 | 11626196 | 6 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | Y | 0 | 40 | MG | QD | |||||||
116261966 | 11626196 | 7 | SS | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | Y | 0 | 20 | MG | QD | |||||||
116261966 | 11626196 | 8 | SS | INOTUZUMAB OZOGAMICIN | INOTUZUMAB OZOGAMICIN | 1 | Intravenous (not otherwise specified) | 0 | 1.5 | MG | QD | ||||||||
116261966 | 11626196 | 9 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 0 | 720 | MG | QD | |||||||
116261966 | 11626196 | 10 | SS | MABTHERA | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 0 | 375 | MG/M**2 | QD | |||||||
116261966 | 11626196 | 11 | SS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | U | 0 | 2 | MG | QD | |||||||
116261966 | 11626196 | 12 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Oral | 0 | 300 | MG | QD | ||||||||
116261966 | 11626196 | 13 | C | ALLOPURINOL. | ALLOPURINOL | 1 | 0 | ||||||||||||
116261966 | 11626196 | 14 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 0 | 75 | MG | QD | ||||||||
116261966 | 11626196 | 15 | C | CHLORPHENAMINE | CHLORPHENIRAMINE MALEATE | 1 | Intravenous (not otherwise specified) | 0 | 10 | MG | QD | ||||||||
116261966 | 11626196 | 16 | C | DIGOXIN. | DIGOXIN | 1 | Unknown | 0 | |||||||||||
116261966 | 11626196 | 17 | C | DIGOXIN. | DIGOXIN | 1 | Oral | 0 | 125 | UG | QD | ||||||||
116261966 | 11626196 | 18 | C | FILGRASTIM | FILGRASTIM | 1 | Subcutaneous | 0 | 300 | UG | QD | ||||||||
116261966 | 11626196 | 19 | C | FLUCONAZOLE. | FLUCONAZOLE | 1 | Oral | 0 | 50 | MG | QD | ||||||||
116261966 | 11626196 | 20 | C | HYDROXYCHLOROQUINE | HYDROXYCHLOROQUINE | 1 | Oral | 0 | 200 | MG | BID | ||||||||
116261966 | 11626196 | 21 | C | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
116261966 | 11626196 | 22 | C | METOCLOPRAMIDE. | METOCLOPRAMIDE | 1 | Oral | AS NECESSARY | 0 | ||||||||||
116261966 | 11626196 | 23 | C | ONDANSETRON | ONDANSETRON | 1 | Oral | 0 | 8 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
116261966 | 11626196 | 1 | Diffuse large B-cell lymphoma |
116261966 | 11626196 | 2 | Neoplasm malignant |
116261966 | 11626196 | 3 | Gastrointestinal haemorrhage |
116261966 | 11626196 | 4 | Diffuse large B-cell lymphoma |
116261966 | 11626196 | 5 | Neoplasm malignant |
116261966 | 11626196 | 6 | Cardiac disorder |
116261966 | 11626196 | 8 | Diffuse large B-cell lymphoma |
116261966 | 11626196 | 9 | Diffuse large B-cell lymphoma |
116261966 | 11626196 | 10 | Neoplasm malignant |
116261966 | 11626196 | 11 | Diffuse large B-cell lymphoma |
116261966 | 11626196 | 12 | Prophylaxis |
116261966 | 11626196 | 13 | Gout |
116261966 | 11626196 | 14 | Aortic valve replacement |
116261966 | 11626196 | 15 | Unevaluable event |
116261966 | 11626196 | 16 | Atrial fibrillation |
116261966 | 11626196 | 18 | White blood cell count |
116261966 | 11626196 | 19 | Antifungal prophylaxis |
116261966 | 11626196 | 20 | Rheumatoid arthritis |
116261966 | 11626196 | 21 | Rheumatoid arthritis |
116261966 | 11626196 | 22 | Vomiting |
116261966 | 11626196 | 23 | Vomiting |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
116261966 | 11626196 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
116261966 | 11626196 | Blood lactic acid increased | |
116261966 | 11626196 | Hyponatraemia | |
116261966 | 11626196 | Lower respiratory tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
116261966 | 11626196 | 1 | 20150820 | 20150824 | 0 | |
116261966 | 11626196 | 3 | 20150826 | 0 | ||
116261966 | 11626196 | 4 | 20150820 | 20150820 | 0 | |
116261966 | 11626196 | 6 | 20150826 | 0 | ||
116261966 | 11626196 | 8 | 20150821 | 20150821 | 0 | |
116261966 | 11626196 | 9 | 20150820 | 20150820 | 0 | |
116261966 | 11626196 | 11 | 20150820 | 20150820 | 0 | |
116261966 | 11626196 | 12 | 20150815 | 20150826 | 0 | |
116261966 | 11626196 | 14 | 20150826 | 0 | ||
116261966 | 11626196 | 15 | 20150820 | 20150820 | 0 | |
116261966 | 11626196 | 16 | 20150815 | 20150826 | 0 | |
116261966 | 11626196 | 17 | 20150826 | 0 | ||
116261966 | 11626196 | 18 | 20150823 | 20150826 | 0 | |
116261966 | 11626196 | 19 | 20150815 | 20150826 | 0 | |
116261966 | 11626196 | 20 | 20150814 | 20150826 | 0 | |
116261966 | 11626196 | 21 | 201107 | 20150826 | 0 | |
116261966 | 11626196 | 22 | 20150820 | 20150826 | 0 | |
116261966 | 11626196 | 23 | 20150820 | 20150820 | 0 |